-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmanet News, May 14 Recently, Chia Tai Tianqing Pharmaceutical Group's application for the imitation of Aprepitant Capsule 4 was approved, becoming the second domestic pharmaceutical company to be approved for the product and deemed to have been reviewed.
Aprepitant is an antiemetic drug with a new mechanism of action developed by Merck.
Its global sales peaked at more than US$500 million in 2017.
In addition, the company's sunitinib malate capsules have entered the "under approval" status and are expected to be approved in the near future.
Aprepitant is an antiemetic drug with a new mechanism of action developed by Merck.
Its global sales peaked at more than US$500 million in 2017.
In addition, the company's sunitinib malate capsules have entered the "under approval" status and are expected to be approved in the near future.
Figure 1: Details of approved products
Source: NMPA official website
Aprepitant is mainly used to prevent acute and delayed nausea and vomiting during the initial and repeated treatment of highly emetic anti- tumor chemotherapy.
At present, in addition to Merck’s approval for import in the domestic market, Qilu Pharmaceutical was approved in July 2020.
The first batch of imitations + the first review, Chia Tai Tianqing Pharmaceutical Group became the second (approved + review).
At present, in addition to Merck’s approval for import in the domestic market, Qilu Pharmaceutical was approved in July 2020.
The first batch of imitations + the first review, Chia Tai Tianqing Pharmaceutical Group became the second (approved + review).
Figure 2: Sales of Aprepitant Capsules
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Minai.
com, in 2020 , aprepitant capsules will be among the top 20 terminal antiemetics and anti-nausea products in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
Ranked in TOP2 with sales of more than 200 million yuan, after Qilu joined the war, Merck's market share began to decline.
com, in 2020 , aprepitant capsules will be among the top 20 terminal antiemetics and anti-nausea products in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
Ranked in TOP2 with sales of more than 200 million yuan, after Qilu joined the war, Merck's market share began to decline.
Table 1: High-end generic drugs approved by Chia Tai Tianqing Pharmaceutical Group since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since 2021, CP Tianqing Pharmaceutical Group has approved 3 high-end generic drugs (Category 3, Category 4) for listing.
Esomeprazole Magnesium Enteric-coated Capsules and Aprepitant Capsules are the second domestic ones.
Approved, Enpagliflozin is the third domestic manufacturer to be approved, with obvious market advantages.
In the fourth batch of national procurement, CP Tianqing Pharmaceutical Group's Esomeprazole Magnesium Enteric-coated Capsules and Engligliflozin Tablets both won the bids.
It is expected that sales will increase rapidly after implementation in various regions.
Esomeprazole Magnesium Enteric-coated Capsules and Aprepitant Capsules are the second domestic ones.
Approved, Enpagliflozin is the third domestic manufacturer to be approved, with obvious market advantages.
In the fourth batch of national procurement, CP Tianqing Pharmaceutical Group's Esomeprazole Magnesium Enteric-coated Capsules and Engligliflozin Tablets both won the bids.
It is expected that sales will increase rapidly after implementation in various regions.
Table 2: Chia Tai Tianqing Pharmaceutical Group's listing applications under review since 2018
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Chia Tai Tianqing Pharmaceutical Group’s applications for the listing of generic drugs under review from 2018 to the present are all declared according to the new classification.
After approval, they are deemed to have been reviewed.
Among them, sunitinib malate capsules have entered the administrative approval stage, and etrobopar ethanolamine tablets , Lenvatinib mesylate capsules, vothiaxetine hydrobromide tablets, sacubitril and valsartan sodium tablets, methacholine for inhalation and everolimus tablets are expected to hit the first imitation.
After approval, they are deemed to have been reviewed.
Among them, sunitinib malate capsules have entered the administrative approval stage, and etrobopar ethanolamine tablets , Lenvatinib mesylate capsules, vothiaxetine hydrobromide tablets, sacubitril and valsartan sodium tablets, methacholine for inhalation and everolimus tablets are expected to hit the first imitation.
Pharmanet News, May 14 Recently, Chia Tai Tianqing Pharmaceutical Group's application for the imitation of Aprepitant Capsule 4 was approved, becoming the second domestic pharmaceutical company to be approved for the product and deemed to have been reviewed.
Aprepitant is an antiemetic drug with a new mechanism of action developed by Merck.
Its global sales peaked at more than US$500 million in 2017.
In addition, the company's sunitinib malate capsules have entered the "under approval" status and are expected to be approved in the near future.
Aprepitant is an antiemetic drug with a new mechanism of action developed by Merck.
Its global sales peaked at more than US$500 million in 2017.
In addition, the company's sunitinib malate capsules have entered the "under approval" status and are expected to be approved in the near future.
Figure 1: Details of approved products
Source: NMPA official website
Aprepitant is mainly used to prevent acute and delayed nausea and vomiting during the initial and repeated treatment of highly emetic anti- tumor chemotherapy.
At present, in addition to Merck’s approval for import in the domestic market, Qilu Pharmaceutical was approved in July 2020.
The first batch of imitations + the first review, Chia Tai Tianqing Pharmaceutical Group became the second (approved + review).
At present, in addition to Merck’s approval for import in the domestic market, Qilu Pharmaceutical was approved in July 2020.
The first batch of imitations + the first review, Chia Tai Tianqing Pharmaceutical Group became the second (approved + review).
Figure 2: Sales of Aprepitant Capsules
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Minai.
com, in 2020 , aprepitant capsules will be among the top 20 terminal antiemetics and anti-nausea products in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
Ranked in TOP2 with sales of more than 200 million yuan, after Qilu joined the war, Merck's market share began to decline.
com, in 2020 , aprepitant capsules will be among the top 20 terminal antiemetics and anti-nausea products in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
Ranked in TOP2 with sales of more than 200 million yuan, after Qilu joined the war, Merck's market share began to decline.
Table 1: High-end generic drugs approved by Chia Tai Tianqing Pharmaceutical Group since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since 2021, CP Tianqing Pharmaceutical Group has approved 3 high-end generic drugs (Category 3, Category 4) for listing.
Esomeprazole Magnesium Enteric-coated Capsules and Aprepitant Capsules are the second domestic ones.
Approved, Enpagliflozin is the third domestic manufacturer to be approved, with obvious market advantages.
In the fourth batch of national procurement, CP Tianqing Pharmaceutical Group's Esomeprazole Magnesium Enteric-coated Capsules and Engligliflozin Tablets both won the bids.
It is expected that sales will increase rapidly after implementation in various regions.
Esomeprazole Magnesium Enteric-coated Capsules and Aprepitant Capsules are the second domestic ones.
Approved, Enpagliflozin is the third domestic manufacturer to be approved, with obvious market advantages.
In the fourth batch of national procurement, CP Tianqing Pharmaceutical Group's Esomeprazole Magnesium Enteric-coated Capsules and Engligliflozin Tablets both won the bids.
It is expected that sales will increase rapidly after implementation in various regions.
Table 2: Chia Tai Tianqing Pharmaceutical Group's listing applications under review since 2018
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Chia Tai Tianqing Pharmaceutical Group’s applications for the listing of generic drugs under review from 2018 to the present are all declared according to the new classification.
After approval, they are deemed to have been reviewed.
Among them, sunitinib malate capsules have entered the administrative approval stage, and etrobopar ethanolamine tablets , Lenvatinib mesylate capsules, vothiaxetine hydrobromide tablets, sacubitril and valsartan sodium tablets, methacholine for inhalation and everolimus tablets are expected to hit the first imitation.
After approval, they are deemed to have been reviewed.
Among them, sunitinib malate capsules have entered the administrative approval stage, and etrobopar ethanolamine tablets , Lenvatinib mesylate capsules, vothiaxetine hydrobromide tablets, sacubitril and valsartan sodium tablets, methacholine for inhalation and everolimus tablets are expected to hit the first imitation.
Pharmanet News, May 14 Recently, Chia Tai Tianqing Pharmaceutical Group's application for the imitation of Aprepitant Capsule 4 was approved, becoming the second domestic pharmaceutical company to be approved for the product and deemed to have been reviewed.
Aprepitant is an antiemetic drug with a new mechanism of action developed by Merck.
Its global sales peaked at more than US$500 million in 2017.
In addition, the company's sunitinib malate capsules have entered the "under approval" status and are expected to be approved in the near future.
Aprepitant is an antiemetic drug with a new mechanism of action developed by Merck.
Its global sales peaked at more than US$500 million in 2017.
In addition, the company's sunitinib malate capsules have entered the "under approval" status and are expected to be approved in the near future.
Figure 1: Details of approved products
Source: NMPA official website
Aprepitant is mainly used to prevent acute and delayed nausea and vomiting during the initial and repeated treatment of highly emetic anti- tumor chemotherapy.
At present, in addition to Merck’s approval for import in the domestic market, Qilu Pharmaceutical was approved in July 2020.
The first batch of imitations + the first review, Chia Tai Tianqing Pharmaceutical Group became the second (approved + review).
Tumor tumor tumorAt present, in addition to Merck’s approval for import in the domestic market, Qilu Pharmaceutical was approved in July 2020.
The first batch of imitations + the first review, Chia Tai Tianqing Pharmaceutical Group became the second (approved + review).
Figure 2: Sales of Aprepitant Capsules
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Minai.
com, in 2020 , aprepitant capsules will be among the top 20 terminal antiemetics and anti-nausea products in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
Ranked in TOP2 with sales of more than 200 million yuan, after Qilu joined the war, Merck's market share began to decline.
Hospital hospital hospitalcom, in 2020 , aprepitant capsules will be among the top 20 terminal antiemetics and anti-nausea products in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
Ranked in TOP2 with sales of more than 200 million yuan, after Qilu joined the war, Merck's market share began to decline.
Table 1: High-end generic drugs approved by Chia Tai Tianqing Pharmaceutical Group since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since 2021, CP Tianqing Pharmaceutical Group has approved 3 high-end generic drugs (Category 3, Category 4) for listing.
Esomeprazole Magnesium Enteric-coated Capsules and Aprepitant Capsules are the second domestic ones.
Approved, Enpagliflozin is the third domestic manufacturer to be approved, with obvious market advantages.
In the fourth batch of national procurement, CP Tianqing Pharmaceutical Group's Esomeprazole Magnesium Enteric-coated Capsules and Engligliflozin Tablets both won the bids.
It is expected that sales will increase rapidly after implementation in various regions.
Esomeprazole Magnesium Enteric-coated Capsules and Aprepitant Capsules are the second domestic ones.
Approved, Enpagliflozin is the third domestic manufacturer to be approved, with obvious market advantages.
In the fourth batch of national procurement, CP Tianqing Pharmaceutical Group's Esomeprazole Magnesium Enteric-coated Capsules and Engligliflozin Tablets both won the bids.
It is expected that sales will increase rapidly after implementation in various regions.
Table 2: Chia Tai Tianqing Pharmaceutical Group's listing applications under review since 2018
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Chia Tai Tianqing Pharmaceutical Group’s applications for the listing of generic drugs under review from 2018 to the present are all declared according to the new classification.
After approval, they are deemed to have been reviewed.
Among them, sunitinib malate capsules have entered the administrative approval stage, and etrobopar ethanolamine tablets , Lenvatinib mesylate capsules, vothiaxetine hydrobromide tablets, sacubitril and valsartan sodium tablets, methacholine for inhalation and everolimus tablets are expected to hit the first imitation.
After approval, they are deemed to have been reviewed.
Among them, sunitinib malate capsules have entered the administrative approval stage, and etrobopar ethanolamine tablets , Lenvatinib mesylate capsules, vothiaxetine hydrobromide tablets, sacubitril and valsartan sodium tablets, methacholine for inhalation and everolimus tablets are expected to hit the first imitation.
